By Counterforce Health Team in Somatuline Depot (lanreotide) —

How to Get Somatuline Depot (Lanreotide) Covered by Humana in California: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Somatuline Depot (Lanreotide) Covered by Humana in California

Fastest path: Humana requires prior authorization for Somatuline Depot, often with step therapy requiring octreotide LAR trial first. If denied, file internal appeals within 65 days, then escalate to federal Independent Review Entity (IRE) for Medicare Advantage plans or California Independent Medical Review (IMR) for state-regulated plans.

First step today: Have your endocrinologist submit a complete prior authorization request through Humana's provider portal with diagnosis codes, prior therapy documentation, and medical necessity letter citing Humana's lanreotide policy criteria.

Table of Contents

  1. When Formulary Alternatives Make Sense
  2. Typical Alternatives to Somatuline Depot
  3. Pros and Cons Overview
  4. Exception Strategy for Somatuline Depot
  5. Switching Logistics and Provider Coordination
  6. Re-trying for Somatuline Depot Later
  7. Appeals Playbook for California
  8. Common Denial Reasons & Solutions
  9. FAQ

When Formulary Alternatives Make Sense

Humana Medicare Advantage plans typically require trying octreotide-based somatostatin analogs first before approving Somatuline Depot (lanreotide) for acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), or carcinoid syndrome.

Coverage Criteria at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required for all Humana Medicare plans Humana PA Lists
Step Therapy Must try octreotide LAR first (unless contraindicated) Humana Lanreotide Policy
Formulary Tier Specialty tier (high copay) Humana Drug Lists
Diagnosis Codes E22.0 (acromegaly), C78.00 (GEP-NET), E34.0 (carcinoid) Humana PA criteria
Appeals Deadline 65 days from denial notice Medicare Part D regulations

Alternatives may be appropriate when:

  • You haven't tried octreotide LAR at maximum tolerated doses
  • Cost considerations are primary (octreotide typically lower tier)
  • Injection frequency preferences differ (monthly vs. every 4 weeks)
  • Your condition is stable and well-controlled on current therapy

Typical Alternatives to Somatuline Depot

Primary Formulary Alternative (First-Line)

Octreotide LAR (Sandostatin LAR)

  • Humana's preferred somatostatin analog for acromegaly and NETs
  • Available as brand and biosimilar versions
  • Administered intramuscularly every 4 weeks
  • Lower formulary tier than lanreotide on most Humana plans

Secondary Options

Short-acting octreotide (Sandostatin injection)

  • Used for symptom control in carcinoid syndrome
  • May be required before long-acting formulations
  • Subcutaneous injection 2-3 times daily

Pasireotide (Signifor/Signifor LAR)

  • Reserved for acromegaly uncontrolled on octreotide/lanreotide
  • Higher risk of hyperglycemia and diabetes
  • Requires extensive prior therapy documentation

Everolimus (Afinitor)

  • For progressive neuroendocrine tumors
  • Often used in combination with somatostatin analogs
  • Different mechanism of action (mTOR inhibitor)

Pros and Cons Overview

Octreotide LAR vs. Somatuline Depot

Factor Octreotide LAR Somatuline Depot
Access Preferred by Humana, lower tier Requires PA, higher tier
Administration IM injection, clinic-based Deep SC, can be home-administered
Frequency Every 4 weeks Every 4 weeks
Efficacy Similar biochemical control rates Similar biochemical control rates
Side Effects GI symptoms, gallstones, bradycardia Similar profile to octreotide
Cost Lower copay on most plans Higher copay, specialty tier

Testing and Monitoring Requirements

Both medications require:

  • Baseline gallbladder ultrasound
  • Regular monitoring of GH/IGF-1 (acromegaly) or tumor markers
  • Glucose monitoring (risk of hyperglycemia)
  • Cardiac monitoring (bradycardia risk)
  • Liver function tests

Exception Strategy for Somatuline Depot

When to Request an Exception

Request a formulary exception or prior authorization override when:

  1. Prior octreotide failure or intolerance
    • Inadequate biochemical control at maximum doses
    • Severe injection site reactions
    • Intolerable side effects (GI, cardiac, endocrine)
  2. Contraindications to octreotide
    • Severe bradycardia or heart block
    • Uncontrolled diabetes (for pasireotide)
    • Allergy or hypersensitivity
  3. Stable on lanreotide from previous plan
    • Risk of disease destabilization with switch
    • Prior hospitalizations when uncontrolled

Evidence That Strengthens Your Case

Medical Necessity Letter Should Include:

  • Specific diagnosis with ICD-10 codes
  • Complete prior therapy history with dates, doses, and outcomes
  • Objective measures (GH/IGF-1 levels, imaging, symptom diaries)
  • Citation of FDA labeling for approved indications
  • Reference to endocrine society guidelines supporting use
Tip: Humana's own lanreotide policy states that prior brand requirements "do not apply to Medicare Part B requests," which may help if your medication is billed medically rather than through pharmacy benefits.

Switching Logistics and Provider Coordination

Step-by-Step: Transitioning Between Somatostatin Analogs

  1. Verify current coverage status
    • Check Humana formulary for your specific plan
    • Confirm PA requirements and step therapy rules
  2. Coordinate with your endocrinologist
    • Discuss clinical rationale for preferred agent
    • Plan monitoring schedule for transition period
    • Document baseline labs and symptoms
  3. Submit prior authorization
    • Use Humana provider portal or electronic PA system
    • Include complete medical records and specialist letter
    • Request expedited review if clinically urgent
  4. Plan injection logistics
    • Confirm specialty pharmacy for drug delivery
    • Schedule first injection appointment
    • Ensure no gap in therapy during transition

Pharmacy Coordination

Somatuline Depot is typically dispensed through CenterWell Specialty Pharmacy (Humana's specialty pharmacy) for Medicare plans. Ensure:

  • Prior authorization is approved before shipment
  • Injection training is scheduled if switching from IM to SC route
  • Backup supply plan if delivery delays occur

Re-trying for Somatuline Depot Later

What to Document During Alternative Therapy

If you start with octreotide LAR or another alternative, carefully document:

Clinical Response Tracking:

  • Monthly symptom diaries (flushing, diarrhea for carcinoid syndrome)
  • Laboratory results every 3 months (GH, IGF-1, chromogranin A)
  • Imaging studies per standard intervals
  • Quality of life assessments

Adverse Events:

  • Injection site reactions (photos, measurements)
  • GI symptoms (frequency, severity, impact on nutrition)
  • Cardiac effects (heart rate, blood pressure logs)
  • Metabolic effects (glucose levels, weight changes)

Treatment Burden:

  • Missed work/activities for injections
  • Travel difficulties for clinic visits
  • Impact on daily functioning
From our advocates: Patients who maintain detailed symptom logs and work closely with their endocrinologist to document treatment responses have significantly higher success rates when requesting coverage for their preferred somatostatin analog after an alternative trial.

Timing Your Resubmission

Resubmit for Somatuline Depot when you have:

  • At least 3-6 months of documented alternative therapy
  • Clear evidence of inadequate control or intolerance
  • Updated specialist letter supporting the switch
  • New lab results showing suboptimal disease control

Appeals Playbook for California

Humana Medicare Advantage Appeals Process

Level 1: Internal Appeal (Redetermination)

  • Deadline: 65 days from denial notice
  • Timeline: 7 calendar days for standard, 72 hours for expedited
  • How to file: Humana member services or provider portal
  • Required: Denial letter, medical records, updated physician letter

Level 2: Independent Review Entity (IRE)

  • Automatic: If Level 1 upheld
  • Timeline: 30 days for standard, 7 days for expedited
  • Reviewer: Independent medical experts
  • Binding: Yes, Humana must comply if overturned

California State Options

For state-regulated plans, California offers Independent Medical Review (IMR):

When IMR Applies:

  • HMO or PPO plans regulated by DMHC or CDI
  • After at least one internal appeal
  • Denial based on medical necessity

How to Request IMR:

  • Contact DMHC Help Center at 888-466-2219
  • Submit application within required timeframe
  • Include all medical records and appeal decisions

Success Factors for IMR:

  • FDA-approved indication clearly documented
  • Failed alternatives well-documented
  • Strong specialist support with clinical rationale
  • Alignment with recognized treatment guidelines

Common Denial Reasons & Solutions

Denial Reason How to Overturn
"Not medically necessary" Provide specialist letter citing FDA labeling and treatment guidelines
"Step therapy required" Document octreotide failure, intolerance, or contraindication
"Non-formulary drug" Request formulary exception with medical necessity documentation
"Quantity limits exceeded" Submit dosing rationale based on clinical response and guidelines
"Experimental/investigational" Cite FDA approval and established clinical use

Scripts for Common Situations

Patient calling Humana: "I'm calling about a prior authorization denial for Somatuline Depot. My denial letter is dated [date] and the reference number is [number]. I'd like to understand the specific reason for denial and how to file an appeal. Can you also confirm if this goes through Medicare Part D or Part B benefits?"

Provider requesting peer-to-peer: "I'm requesting a peer-to-peer review for [patient name] regarding denied coverage for Somatuline Depot. The patient has acromegaly with inadequate control on octreotide LAR despite maximum dosing. I have documentation of treatment failure and would like to discuss the clinical rationale with your medical director."

FAQ

How long does Humana prior authorization take in California? Standard PA decisions are made within 72 hours for Part D drugs. Expedited reviews are completed within 24 hours if delay could seriously harm health.

What if Somatuline Depot is not on my formulary? You can request a formulary exception through your prescriber. Include medical necessity documentation showing why covered alternatives are not appropriate.

Can I request an expedited appeal? Yes, if waiting for standard review timelines could seriously jeopardize your life, health, or ability to regain maximum function. Your doctor must support the urgency.

Does step therapy apply if I was stable on lanreotide outside California? Step therapy requirements typically apply regardless of prior state. However, you can request an exception based on risk of destabilization and prior treatment success.

How much does Somatuline Depot cost without insurance? List price ranges from $7,928 to $9,348 per monthly injection, depending on strength. Manufacturer assistance programs may be available.

What's the difference between Medicare appeals and California IMR? Medicare Advantage plans use federal appeals (IRE), while state-regulated plans may use California IMR through DMHC or CDI. Check your plan type to determine which applies.

About Counterforce Health

Counterforce Health specializes in turning insurance denials into successful appeals for specialty medications like Somatuline Depot. Our platform analyzes denial letters and plan policies to create evidence-backed appeals that address payers' specific requirements, helping patients access the treatments their doctors prescribe.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. Coverage policies and appeal procedures may change. For personalized assistance with insurance appeals, consider consulting with patient advocacy services or Counterforce Health.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.